S100A11 and non-small cell lung carcinoma: As cPLA2 was upregulated in 64% of NSCLC samples overexpressing S100A11, compared to normal tissues (Fig. 8), targeting TSN or S100A11 may be particularly beneficial for anti-cancer treatment in these cases.